For anyone in Ḩorr looking to source CJC-1295, the first thing to know is that this compound is distributed via specialist online vendors. The core insight for Ḩorr researchers: sourcing CJC-1295 hinges on vendor quality evaluation, not geography — and the framework for evaluating that quality is the same regardless of where you are. A legitimate CJC-1295 supplier's COA needs to show HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all corresponding to the vial you receive. This guide walks Ḩorr researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
CJC-1295: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Ḩorr researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Before assessing any particular supplier, build a clear picture of what a proper COA looks like — so you can identify whether a supplier meets the standard. Endotoxin testing in the COA is essential for any injectable research use — endotoxins from microbial contamination can trigger dangerous inflammatory cascades even at trace quantities. The combination of community reputation data and your own COA analysis is the most effective quality filter — community feedback surfaces recurring issues no single purchase reveals, and vice versa. Hold lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the volume needed for upcoming use and store the rest at −20°C.
Order CJC-1295 — ships to Ḩorr
COA-verified · International tracking · Research grade
All use of CJC-1295 in Ḩorr or anywhere is research use only — this compound is not approved for human therapeutic use, and all handling should comply with standard research safety practices. Lyophilised CJC-1295 should be placed in the freezer at −20°C straight away; repeated freeze-thaw cycles of reconstituted material should be avoided by aliquoting into single-use portions. Endotoxin testing in the CJC-1295 COA is not optional — gram-negative bacterial endotoxins can trigger severe inflammatory responses at trace quantities, and no pricing advantage justifies skipping this verification. PubMed provide the most complete literature coverage for CJC-1295 research; favour indexed journal publications over preprints over conference abstracts or single case observations.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
